COMMUNIQUÉS West-GlobeNewswire

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
15/11/2024
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more [...]
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting
14/11/2024
Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage exchange arthroplasty and highlight a 71% reduction in PJI burden DALLAS, Nov. 14, [...]
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
14/11/2024
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
Precision Optics Receives Initial Production Order for Single-Use Ophthalmic Program
14/11/2024
Second single-use program to move into production this year highlights new growth opportunity for Precision Optics GARDNER, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the [...]
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
14/11/2024
Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer HOUSTON, Nov. [...]
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
14/11/2024
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study [...]
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
14/11/2024
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. , a leading provider [...]
Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024
14/11/2024
Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in [...]
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
14/11/2024
Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, [...]
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
14/11/2024
COVID : Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of clinical rebound and [...]
Precision Optics Reports First Quarter Fiscal Year 2025 Financial Results
14/11/2024
Conference Call Scheduled for today, November 14, 2024, at 5:00pm ET. GARDNER, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced [...]
Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results
14/11/2024
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter [...]
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
14/11/2024
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline data of GRI-0621 readout [...]
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
14/11/2024
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces [...]
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
14/11/2024
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, [...]
TFF Pharmaceuticals Announces It Will Wind Down Operations
14/11/2024
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a [...]
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14/11/2024
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium ( 186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial [...]
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
14/11/2024
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a [...]
Panbela Provides Business Update and Reports Q3 2024 Financial Results
14/11/2024
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]

Pages